Are there peer-reviewed studies on Clevatess?
Are there peer-reviewed studies on Clevatess? Yes, Clevatess (clascoterone) has been extensively studied in peer-reviewed clinical trials, establishing its safety and efficacy profile for treating acne.
Published Clinical Trial Data
The most significant peer-reviewed studies on Clevatess were published in JAAD (Journal of the American Academy of Dermatology) and other dermatology journals. Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials evaluated Clevatess cream 1% in patients aged 9 years and older with facial acne.
Key Study Results
These peer-reviewed studies demonstrated that Clevatess significantly reduced inflammatory and non-inflammatory acne lesions compared to placebo. In the clinical trials:
- Efficacy: Patients showed statistically significant improvements in lesion counts at 12 weeks
- Safety profile: The treatment was well-tolerated with minimal systemic absorption
- Patient demographics: Studies included diverse populations across different age groups
Mechanism of Action Research
Peer-reviewed research has also explored Clevatess's unique mechanism as a topical androgen receptor antagonist. Unlike traditional acne treatments, clascoterone works by blocking androgen receptors in sebaceous glands, addressing one of acne's root causes.
Additional Studies
Beyond the pivotal trials, researchers have published studies examining:
- Long-term safety data
- Hormonal impact assessments
- Comparative effectiveness with other acne treatments
- Pharmacokinetic properties
Ongoing Research
The scientific community continues to investigate Clevatess through additional peer-reviewed studies, including research on optimal treatment duration, combination therapies, and expanded indications.
These peer-reviewed studies provide healthcare providers with evidence-based data to make informed treatment decisions. For specific study details or to discuss whether Clevatess might be appropriate for your acne treatment plan, consult with a qualified dermatologist.
Discussion (0)